Medtronic Inc’s Resolute Integrity™ Drug-Eluting Stent for treating coronary artery disease has been approved by the FDA, after studies showed consistent clinical performance among a wide range of patients, including individuals with diabetes.
Medtronic
New Clinical Programs Will Evaluate Symplicity™ Renal Denervation System In Multiple Conditions
Medtronic’s newly announced patient registry and heart failure studies will inform on the effectiveness of renal denervation.
New Research Suggests Sprint Fidelis Guidance Should Be Reviewed
Higher failure rates identified by researchers may indicate a policy of replacing Sprint Fidelis ICD units that haven’t malfunctioned.
CoreValve US Trial: Extreme Risk Group Enrollment Complete.
Medtronic gets a little closer to market (in USA) with the announcement that CoreValve’s extreme risk group enrollment is now complete.
J&J Loses Current Round In Drug Eluting Stent Patent Lawsuit With Medtronic, Abbott and Boston Scientific
You say sirolimus, I say everolimus… judge says lets call the whole thing off.
CE Mark And Launch For Medtronic’s Endurant® II AAA Stent Graft System
Medtronic’s Endurant® II Stent Graft to repair Abdominal Aortic Aneurysms without open surgery.
FDA Wants Shrinkage Warning on Boston Scientific’s Newly Approved Promus Element™ Stent
Boston Scientific’s Promus Element Drug Eluting Stent was approved by FDA in late November and now the agency has demanded that the company includes a warning on its packaging about the risk of stent shrinkage.
Medtronic To Cut Further $1.2 Billion In 5 Years
Medtronic CFO Gary Ellis’s statement of intent to further reduce cost base.
Medtronic Reports Q2 Sales Growth
Medtronic Inc.has reported higher-than-expected second quarter earnings as sales of newer devices helped make up for an ongoing slump in its best-selling heart and spine implants.
Stent Shrinkage Still In Spotlight. FDA Wades In.
FDA is taking a proactive stance and working with manufacturers to understand the issue of longitudinal compression in next generation Drug-Eluting Stents.
Retrospective Study Shows New Device Significantly Reduces Blood Loss and Transfusions in Adolescent Scoliosis Corrective Surgery
New study demonstrates the effectiveness of the Aquamantys(R) System in limiting blood loss and reducing transfusions during spinal corrective surgery.
Medtronic Resolute® Drug-Eluting Stent Shows Strong Results, Even in Challenging Diabetes Patients with Coronary Disease
Pooled Data Analyses to Be Presented at TCT 2011 Demonstrate Heart Device’s Consistently Positive Performance Across Multiple Clinical Studies
Researcher Reports Raised Cancer Risk for Medtronic’s Infuse
Researcher’s findings on BMPs, reflected a 2.5 times greater risk of developing cancer one year after the product was used and a five times greater risk after three years.
Medtronic Announces Global Launch of the T2 Altitude™ Expandable Corpectomy Device
Medtronic’s latest advancement in expandable cage technology for surgeons, hospitals and patients
Medtronic Introduces New Procedure for Minimally Invasive Spinal Fusion
Medtronic introduces a midline laminectomy approach for Minimally Invasive Spinal Fusion.
Longitudinal Compression in Drug-Eluting Stents on the Agenda
Longitudinal Compression of Drug Eluting Stents with resultant potential shrinkage will be reviewed at the Transcatheter Cardiovascular Therapeutics meeting in San Francisco next week